Provide data update from RP2 Phase 1 clinical trial
Delivered by the deadline
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 9 Feb 2023
- Due
- 31 Dec 2023
- Delivered
- 8 Nov 2023
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“The Company continues to enroll patients in the expansion cohorts of the Phase 1 clinical trial evaluating RP2 in patients with tumor types of particular interest... with a data update expected in H2 2023.”
What we found
Evidence strength A What the grades mean
The company presented updated data from the RP2 Phase 1 clinical trial, specifically regarding metastatic uveal melanoma patients, at the International Society for Melanoma Research Congress in November 2023.
-
A Replimune Group, Inc. 8-K filed 2024-02-08
“The Company presented positive safety and efficacy data from a cohort of metastatic uveal melanoma patients enrolled in the open-label, multicenter Phase 1 study of RP2... on November 8, 2023.” ✓ confirmed on the page
Market reaction: the shares moved +6.6% against the S&P 500 over the three sessions around the disclosure (7 Feb 2024 to 12 Feb 2024). What this measures
Checked 1 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical readout
- Indicative materiality
- Medium rules
- Action
- Provide
- Deliverable
- RP2 Phase 1 clinical trial data update
- Language
- Expected (“expects”, “plans”)
- In the company’s control
- High
- Specificity
- High
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Claude (Anthropic), re-read the evidence without being told the outcome and reached the same answer.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you Replimune Group, Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2023-REPL-002703 · Corrections policy